Quanterix Corporation - QTRX STOCK NEWS

Quanterix Corporation (NASDAQ: QTRX) announced that its Simoa® phospho-Tau 181 blood test has received Breakthrough Device designation from the FDA for aiding in the diagnostic evaluation of Alzheimer’s Disease. This designation supports faster development and review processes, aiming for earlier, non-invasive diagnosis of the disease. The test is intended for adult patients over 50 with cognitive impairment and is not a standalone diagnostic tool. The Breakthrough Device designation reflects Quanterix's commitment to advancing precision health through innovative diagnostics.

Quanterix Corporation (NASDAQ: QTRX) hosted a webinar on September 16, 2021, discussing ultra-sensitive COVID-19 detection for asymptomatic individuals. The event featured Kevin Hrusovsky and pathologist Dr. John Roback, highlighting Emory University’s effective SARS-CoV-2 screening program, which has tested over 120,000 samples. The webinar emphasized the importance of Simoa technology in advancing preventative medicine, particularly in infectious diseases and other health areas. The recording is available on Quanterix’s website.

Quanterix Corporation (NASDAQ: QTRX) announced the expansion of the Emergency Use Authorization (EUA) for its Simoa SARS-CoV-2 N Protein Antigen Test. This test is now authorized for use with nasal swab and saliva samples, making it the first antigen test approved for saliva. The test is validated against all CDC-designated Variants of Concern, including the Delta variant. This expansion aims to enhance less-invasive testing options and improve SARS-CoV-2 testing capacity across the U.S.

Quanterix Corporation (NASDAQ: QTRX) announced a webinar featuring CEO Kevin Hrusovsky and Dr. John Roback from Emory Medical Laboratories. The event, scheduled for September 16, 2021, will discuss the implementation of a SARS-CoV-2 screening program at Emory and showcase Simoa technology's ability to detect viral antigens in non-invasive samples. Hrusovsky will highlight how advancements in COVID and neurological biomarkers are pivotal for preventative medicine and precision health.

Quanterix Corporation (NASDAQ: QTRX) released a statement addressing media reports concerning its engagement with Cassava Sciences. The company clarified that it performed sample testing using blinded samples from Cassava but did not interpret the results or prepare the accompanying data presented at the Alzheimer’s Association International Conference (AAIC) in July 2021. Quanterix's Simoa technology is trusted by major pharmaceutical companies and is extensively used in research across various diseases, including Alzheimer’s. The company is committed to advancing precision health through innovative biomarker analysis.

Quanterix Corporation (NASDAQ: QTRX) announced that its Chairman and CEO, Kevin Hrusovsky, will participate in a virtual fireside chat at the Canaccord Genuity 41st Annual Growth Conference on August 12 at 12:00 p.m. ET. He will also conduct virtual meetings with institutional investors. The live webcast will be available on Quanterix's investor relations website, with replays accessible for 90 days. Quanterix focuses on digitizing biomarker analysis through its Simoa technology, enhancing early disease detection and treatment methods across various therapeutic areas.

Quanterix Corporation (NASDAQ: QTRX) announced that Eli Lilly presented new data from the Phase 2 TRAILBLAZER-ALZ study at AAIC 2021, utilizing Quanterix’ Simoa® technology. The data indicate a significant reduction in blood levels of phosphorylated Tau protein after treatment with donanemab, highlighting Simoa’s role in Alzheimer’s research. More than 80 abstracts based on Simoa technology were presented at the event. Quanterix continues to focus on advancing therapies for neurodegenerative diseases, aiming for earlier detection and improved patient outcomes.

Quanterix Corporation (NASDAQ: QTRX) reported significant financial growth for Q2 2021, achieving a GAAP total revenue of $25.4M, up 93% from $13.1M in Q2 2020. Non-GAAP total revenue increased 86% to $24.4M. Product revenue soared by 175% to $18.7M. Gross margins improved, with Q2 GAAP gross margin at 54.7%, up from 39.7% in 2020. The company also made strides in diagnostics for neurodegenerative diseases, enhancing methodologies for disease progression monitoring. Leadership changes included the appointment of Masoud Toloue as President and Michael Doyle as CFO.

Quanterix Corporation (NASDAQ: QTRX) will release its second quarter 2021 financial results on August 5, 2021, after market close. A conference call is scheduled for 4:30 PM ET, hosted by CEO Kevin Hrusovsky, to discuss the results and provide a business update. Investors can join by calling 833-686-9351 (domestic) or 612-979-9890 (international) and using conference ID 2299526. A live webcast of the call will be available at this link.